Knowledge HQ

Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer treatment with success in treating specific subsets of B cell leukemia, lymphoma, and multiple myeloma.  Much attention is focused on expanding CAR-T cell therapy to other hematologic malignancies and solid tumors. Central to engineering effective CAR-T cell therapies is a detailed understanding of the signaling cascades that regulate CAR-T cells, including trafficking and tumor infiltration, preventing antigen escape, resisting immunosuppressive responses, and ameliorating potentially fatal toxicity. Detailed characterization of extracellular, membrane-bound, and intracellular signaling molecules is required, often with limited and complex sample types.

Current methods of final formulation fill and finish either require manual processing which has the potential to result in operator error, or utilized automated systems with limited capabilities. Manual methods or semi-automated systems may present the risk of increased exposure time of cells to DMSO within the cryoprotectant, causing a reduction in post-thaw viability and recovery. The Cue Cell Processing System is a functionally closed and fully automated instrument with enhanced system functionalities for F/F/F of Cell and Gene therapy products

G-Rex bioreactors from Wilson Wolf are designed to be used in a "fill-and-forget" manufacturing workflow with Bio-Techne reagents and cytokines. During T-cell expansion, manual interventions for media change and cytokine supplementation can be eliminated. This reduces the risk of contamination and greatly streamlines manufacturing workflows while reducing reagent and overhead costs.

The case study illustrates ScaleReady's effective use of technology and tailored strategies to overcome AgonOx's challenges. Through detailed analysis and strategic implementation of ScaleReady technology, analytics, and automation, ScaleReady achieved significant improvements in customer satisfaction and operational efficiency.  

TcBuster-MTM (TcB-MTM) is a commercially available non-viral transposase-based editing platform that overcomes current viral limitations. TcBuster is found in the red flour beetle and is a member of the hAT family of transposases. Using directed evolution, we engineered a hyperactive mutant (TcB-M) that has improved transposition rates using less mRNA transposase and NanoplasmidTM DNA transposon.

Current iNK differentiation protocols typically utilize xenogenic feeder cells, which could be problematic for patient safety, or they lack robustness and are highly variable in differentiation efficiency. Using animal-free small molecules and recombinant proteins, Bio-Techne developed a feeder-free differentiation process to reliably generate iNKs at scale by optimizing for CD34+ hematopoietic stem cells (iHSC) prior to downstream NK differentiation.

Aliquot accuracy whitepaper provides an in-depth look at how the Cue® Cell Processing System ensures consistency and quality in cell therapy products.

Download the ExCellerate NK Media Feeder-Cell G-Rex Culture Process

Download the protocol to support a feeder-free process in G-Rex cell culture.

ExCellerate NK Media offers a robust and versatile solution for NK cell cultures, designed to transition from research to clinical application seamlessly.